Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Bullboard Posts
Comment by Dwizellon Apr 05, 2019 3:18pm
82 Views
Post# 29589473

RE:RE:RE:A good laugh before the weekend

RE:RE:RE:A good laugh before the weekend
jfm1330 wrote: The "baked into" part is totally crazy. Ignore that" Just ridiculous.


scarlet1967 wrote:
juniper88 wrote: Especially line about "baked in..."  I almost fell of my chair
Analyst Actions: RBC Capital Maintains Sector Perform, $10 TP on Theratechnologies
 
05 Apr 2019 14:03 ET  

02:03 PM EDT, 04/05/2019 (MT Newswires) -- RBC Capital has reiterated its Sector Perform rating and $10 TP on Theratechnologies.

The Trogarzo launch continues to exhibit steady growth, and RBC says it sees peak out-year sales of ~$250 million. The brokerage added that Egrifta sales were also stable q-o-q, with recent NAFLD data potentially augmenting TH's relaunch strategy that could bolster life cycle and revenue in the medium-term. "Overall, we continue to believe Trogarzo and Egrifta should continue to grow, but with peak opportunities mostly baked into shares at current levels."

(TH reported Trogarzo revenues of $6.1 million, slightly above RBC's $5.4 million est. Egrifta sales of $9.0 million were essentially flat q-o-q and below RBC's $10.1 million estimate.)


Baked into SP, what a joke.
The company spent a long time of the whioe CC talking about NASH opportunities mate baked that into your dumb head.
Tragarzo is  still growing despite 44% growth so far how  about baking that into your head.
My best advise is ignoring these idiots.
 




We may all disregard those lazy analysts, but he problem is the market is soooo driven by those  jerks. So the SP will never rise before we will have good US coverage and probably a NASDAQ listing.

Bullboard Posts